By Application
Hot products 
-
Mouse Anti-CARTPT Recombinant Antibody (113612) (CBMAB-C2450-LY)
-
Rat Anti-CD300A Recombinant Antibody (172224) (CBMAB-C0423-LY)
-
Mouse Anti-CD2AP Recombinant Antibody (BR083) (CBMAB-BR083LY)
-
Mouse Anti-COL1A2 Recombinant Antibody (CF108) (V2LY-1206-LY626)
-
Mouse Anti-CCND2 Recombinant Antibody (DCS-3) (CBMAB-G1318-LY)
-
Rat Anti-ADAM10 Recombinant Antibody (V2-179741) (CBMAB-A1103-YC)
-
Mouse Anti-CD164 Recombinant Antibody (CBFYC-0077) (CBMAB-C0086-FY)
-
Mouse Anti-BSN Recombinant Antibody (219E1) (CBMAB-1228-CN)
-
Mouse Anti-BPGM Recombinant Antibody (CBYY-1806) (CBMAB-2155-YY)
-
Mouse Anti-8-oxoguanine Recombinant Antibody (V2-7697) (CBMAB-1869CQ)
-
Mouse Anti-ADRB2 Recombinant Antibody (V2-180026) (CBMAB-A1420-YC)
-
Mouse Anti-CALR Recombinant Antibody (CBFYC-0763) (CBMAB-C0818-FY)
-
Mouse Anti-ALX1 Recombinant Antibody (96k) (CBMAB-C0616-FY)
-
Mouse Anti-CEMIP Recombinant Antibody (3C12) (CBMAB-K0296-LY)
-
Mouse Anti-ADV Recombinant Antibody (V2-503423) (CBMAB-V208-1364-FY)
-
Mouse Anti-BIRC3 Recombinant Antibody (16E63) (CBMAB-C3367-LY)
-
Mouse Anti-APOA1 Monoclonal Antibody (CBFYR0637) (CBMAB-R0637-FY)
-
Mouse Anti-ADGRE2 Recombinant Antibody (V2-261270) (CBMAB-C0813-LY)
-
Mouse Anti-CD63 Recombinant Antibody (CBXC-1200) (CBMAB-C1467-CQ)
-
Mouse Anti-CD8 Recombinant Antibody (C1083) (CBMAB-C1083-LY)
Prostate Cancer
Fig.1 Prostate cancer
Prostate cancer is regarded as glandular cancer or adenocarcinoma, which starts when normal semen-secreting prostate gland cells mutation happens and changes into cancer cells. The majority of prostate cancers are slow-growing; however, some grow relatively quickly. The cancer cells may spread from the prostate to other sites of the body, particularly the lymph nodes and bones. It may initially cause no symptoms. But in later stages it can lead to difficulty urinating, blood in the urine, pain in the pelvis when urinating. The primary risk factors are age, obesity, and family history. Around 99% of cases occur in people over the age of 50 and the average age at the time of diagnosis is around 70. Mutations in BRCA1 and BRCA2 are important risk factors for ovarian cancer and breast cancer in women, have also been implicated in prostate cancer. The expression of Ki-67 by immunohistochemistry may be a significant predictor of patient outcome for men with prostate cancer.
Loading...
Compare
